Rifaximin in cirrhosis: when therapeutic drift meets antimicrobial stewardship

The Lancet Gastroenterology & Hepatology · Published 2026-04-16 · DOI 10.1016/s2468-1253(26)00076-2

Authors being retrieved — see the publisher record. https://doi.org/10.1016/s2468-1253(26)00076-2

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Related articles

• Therapeutic drift or formulation drift: avoiding misconceptions about rifaximin and antimicrobial resistance in cirrhosis · The Lancet Gastroenterology & Hepatology · 2026 · Cites or is cited by this article · Same journal
• Dupilumab versus placebo in adults and adolescents with eosinophilic gastritis (DEGAS): a double-blind, placebo-controlled, phase 2, multicentre, randomised controlled trial · The Lancet Gastroenterology & Hepatology · 2026 · Same journal
• Ethnicity, diversity, and inclusion in gastroenterology: from representation to system performance · The Lancet Gastroenterology & Hepatology · 2026 · Same journal
• Cyclic exclusive enteral nutrition in paediatric Crohn's disease – Authors’ reply · The Lancet Gastroenterology & Hepatology · 2026 · Same journal
• Rome V: refining the language of gut–brain disorders · The Lancet Gastroenterology & Hepatology · 2026 · Same journal
• The spectrum of steatotic liver disease in the USA – Authors’ reply · The Lancet Gastroenterology & Hepatology · 2026 · Same journal
• Drugging the undruggable in pancreatic cancer · The Lancet Gastroenterology & Hepatology · 2026 · Same journal
• Pathophysiology of irritable bowel syndrome · The Lancet Gastroenterology & Hepatology · 2026 · Same journal
• Translating the gut microbiome: where are we? · The Lancet Gastroenterology & Hepatology · 2026 · Same journal
• Combination therapy in metabolic dysfunction-associated steatohepatitis · The Lancet Gastroenterology & Hepatology · 2026 · Same journal